Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI

Reuters

06-05

Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI

On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2541023107"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2541023107\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2541023107?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-05 17:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2541023107","market":"nz","top_or_hot":-1,"title":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-05 17:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250605:nNDL8rFL49:1","article_id":"2541023107","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2541023107","pubTimestamp":1749115564,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI. On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets , has received marketing authorization from the Medicines and Healthcare products Regulatory Agency  of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer  with activating epidermal growth factor receptor  mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Whil","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1191":"制药","03692":"翰森制药","BK1589":"北水核心资产"},"translate_title":"翰森制药Aumolertinib获英国MHRA批准用于非小细胞肺癌治疗，标志着中国自主研发的EGFR-TKI首次海外上市","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9},"content_text":"Hansoh Pharma's Aumolertinib Receives UK MHRA Approval for NSCLC Treatment, Marking First Overseas Launch of China-Developed EGFR-TKI\n    \n\n        On June 4, 2025, Hansoh Pharmaceutical Group Co. Ltd. announced that its innovative drug, Aumolertinib Mesilate Tablets (trade name: Aumseqa in the UK), has received marketing authorization from the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. This approval marks the first overseas launch of a China-developed EGFR-TKI. Aumseqa is approved as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, as well as for those with EGFR T790M mutation-positive NSCLC. The approval signifies a major milestone for Hansoh Pharma, expanding its global reach and bringing innovative cancer treatment options to more patients worldwide.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}